HypoxiaPlanHabNCT02637921
Planetary Habitat Simulation: Bone Metabolism Studies
A study testing Hypoxia, Ambulatory and Normoxia in people with Hypoxia and Bone Resorption, run by University of Nottingham.
Trial summary
Bone losses are well known to occur in response to unloading (in microgravity or during immobilisation) and in patients with chronic obstructive airway disease (COPD). However, it is unknown whether there is an interactive effect between hypoxia and musculoskeletal unloading upon bone and mineral metabolism. Read more about this study
- Who is it for?
- Ages 25 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Hypoxia, Bone Resorption
- What is being tested?
- Hypoxia, Ambulatory and Normoxia
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- No sites listed yet
- Study dates
- Mar 2012to Sep 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Physically and mentally healthy subjects
- Body mass index < 25 kg/m2
- Height 158 - 190 cm
- Waist circumference < 94 cm
- Volunteers that are able to declare their willingness to participate in the entire study
- Willing to be assigned randomly to the three groups
Show all 10Show fewer
- Successfully passing the psychological and medical screening
- competent to sign informed consent
- Slovenian social insurance
- English language fluency
Who cannot join
- Medication required that may interfere with the interpretation of the results
- Bone mineral density (as measured by DEXA) more than 1.5 standard deviations < t score
- Recent sub-standard nutritional status
- Family history of thrombosis or positive response in thrombosis screening procedure.
- (Biochemical analysis of the following parameters: ATIII, High sensitive C-reactive protein, S-Akt., Factor V-Leiden, Prothrombin, Lupus-partial thromboplastin time, Factor II)
- History of: thyroid dysfunction, renal stones, diabetes, allergies, hypertension, hypocalcemia, uric acidaemia, lipidaemia, or hyperhomocysteinaemia
Show all 20Show fewer
- Gastro-esophageal reflux disease or renal function disorder, Hiatus hernia
- History of medical illness
- Smoker within six months prior to the start of the study
- Abuse of drugs, medicine or alcohol
- Participation in another study up to two months before study onset
- No signed consent form before the onset of the experiment
- Blood donors in the past three months before the onset of the experiment
- Vegetarian and Vegans
- Migraines
- History of orthostatic intolerance
- History of vestibular disorders
- Claustrophobia
- metallic implants, osteosynthesis material
- Chronic back pain
About this study
Official title: Planetary Habitat Simulation: The Combined Effects of Bed Rest and Normobaric Hypoxia Upon Bone and Mineral Metabolism (WP3)
Bone losses are well known to occur in response to unloading (in microgravity or during immobilisation) and in patients with chronic obstructive airway disease (COPD). However, it is unknown whether there is an interactive effect between hypoxia and musculoskeletal unloading upon bone and mineral metabolism. Fourteen non-obese men, who are otherwise healthy, will undergo 3x 21-day interventions; normobaric normoxic bed rest (NBR; FiO2=21%), normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and normobaric hypoxic bed rest (HBR; FiO2=14%). The effects of hypoxia and bedrest on bone metabolism and phosphor-calcic homeostasis will be assessed (before and during each intervention, and 14 days after each intervention period) using venous blood sampling, 24hr urine collections, and peripheral quantitative computerized tomography (pQCT).
Read the detailed description
The risk of bone loss in response to immobilization and space flight is widely recognized, with such bone losses occurring predominantly in the legs. Loading forces in the lower extremities are typically low in space and during bed rest, but musculoskeletal loading countermeasures can prevent or reduce bone losses induced in these conditions. Although the primary origin may be of a mechanical nature, bone losses in astronauts and immobilized patients are likely to be modulated by the endocrine and the internal environment.
Bone loss and osteoporosis is also prevalent in those with chronic obstructive pulmonary disease (COPD). The most discussed etiological factors for this condition include lack of physical activity, vitamin-D deficiency, hypogonadism, use of corticosteroids and smoking. However, COPD is associated with tissue hypoxemia and it is unclear whether hypoxia per se will affect bone turnover or metabolism.
The protocol of the current study standardises potential confounding factors, such as physical activity, ambient temperature, hypoxic stimulus and nutritional composition of the diet across all 3 interventions, and aims to extend our knowledge of the effects of hypoxia and bedrest on bone metabolism and phospho-calcic homeostasis.
Fourteen non-obese men, who are otherwise healthy, will be recruited following medical and psychological screening. They will be invited to attend the Olympic Sport Centre, Planica, Slovenia on 3 occasions, with each visit being 31 days in duration and separated by 5 months. Each 31-day visit ('campaign') includes a baseline recording period (5 days), 21 days of intervention, and a recovery period (5 days), with a follow-up visit being carried out 14 days after each intervention. The 3 interventions will be allocated in a randomized, cross over design: i) Normobaric normoxic bed rest (NBR; FiO2=21%), ii) Normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and iii) Normobaric hypoxic bed rest (HBR; FiO2=14%). A standardized, repeating, 14-day dietary menu, comprised of foods commonly consumed in the Slovenian diet, will be applied during all campaigns. Targeted energy intakes will be calculated individually using a modified Benedict-Harris formula, with physical activity factor multipliers of 1.2 for the HBR and NBR campaigns and 1.4 for the HAMB campaign, used to promote energy balance. Body mass will be monitored daily during the campaigns using a gurney incorporating load cells, and whole body composition will be determined before and immediately after each intervention using fan beam dual-emission X-ray absorptiometry. Macronutrient composition of the diet will be approximately 17% protein, 53% carbohydrate and 30% fat, with >1.1g of protein per kg body weight provided per day, and daily salt (sodium chloride) intake being <10g. Food will be provided in weighed portions and subjects will be encouraged to eat all food supplied. However, any food not eaten will be weighed and actual amount consumed recorded in a diet analysis programme.
Participants will have bone mineral content assessed at 5 time points (before, 3 during and one after each intervention) using pQCT scans of the calf and thigh. Horizontal scans will be taken at 4%, 14%, 38%, and 66% of the tibia (assessed from its distal end), and at 4% and 33% of the femur. Twenty-four hour urine collections will be obtained before (2 time points), during (11 time points) and after (3 time points) each intervention, and will be assessed for urinary calcium and phosphate content, and for a marker of bone reabsorption (N-terminal telopeptide). In addition, early morning, fasting venous blood samples will also be taken before (2 time points), and during (5 time points) each intervention. These will be analysed for calcium, phosphate, bone specific alkaline phosphatase, parathyroid hormone, 25-Hydroxyvitamin D, Procollagen-I-N-terminal propeptide and regulators of bone metabolism, (Dickkopf-related protein 1 and Sclerostin).
- Conditions
- Hypoxia, Bone Resorption
- Being tested
- Hypoxia, Ambulatory, Normoxia, Bed Rest, Standardised nutritional intake
- Keywords
- bed rest, bone metabolism
- Medical subject headings
- Hypoxia, Bone Resorption
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HypoxiaOther
21 days confinement in normobaric hypoxic (FiO2 = 14%)
AmbulatoryOther
Participants hava a standardized activity level throughout the intervention
NormoxiaOther
21 days confinement in normobaric normoxic (FiO2 = 21%) environment
Bed RestOther
Participants remain on supine bed rest throughout the intervention
Standardised nutritional intakeOther
Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
| Study group | Role | What they receive |
|---|---|---|
| Hypoxic ambulatory | Active comparator | Participants ambulatory in normobaric hypoxia with standardised nutritional intake Receives: Other: Hypoxia; Other: Ambulatory; Other: Standardised nutritional intake |
| Hypoxic Bed rest | Experimental | Participants are on bed rest in normobaric hypoxia with standardised nutritional intake Receives: Other: Hypoxia; Other: Bed Rest; Other: Standardised nutritional intake |
| Normoxic bed rest | Active comparator | Participants are on bed rest in normobaric normoxia with standardised nutritional intake Receives: Other: Normoxia; Other: Bed Rest; Other: Standardised nutritional intake |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in bone mineral content, from baseline
assessed before (day -5), on days 2, 10 and 21 of the intervention and at the 14-day follow-up visit (40 days after 1st measurement) using pQCT scans of the calf and thigh.
Measured: 40 days
Secondary outcomes (11)
Change in urinary calcium concentration, from baseline
assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 30 days after first measurement)
Measured: 30 days
Change in urinary phosphate concentration, from baseline
assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 31 days after first measurement)
Measured: 31 days
Change in urinary N-terminal telopeptide concentration, from baseline
assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 31 days after first measurement)
Measured: 31 days
Change in fasting serum calcium concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Change in fasting serum phosphate concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Change in fasting serum bone specific alkaline phosphatase concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Change in fasting serum parathyroid hormone concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Change in fasting serum 25-Hydroxyvitamin D concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Change in fasting serum Procollagen-I-N-terminal propeptide concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Change in fasting serum Dickkopf-related protein 1 concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Change in fasting serum Sclerostin concentration, from baseline
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample
Measured: 26 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2015 (estimated)
- Study startMar 2012
- Primary completionNov 2013
- Study completionSep 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypoxiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Collaborators
- Jozef Stefan Institute, DLR German Aerospace Center, KTH Royal Institute of Technology, European Commission
- Responsible party
- Principal investigator, Elizabeth Simpson, University of Nottingham
- Investigators
- Igor Mekjavic, PhD, Study director, Jozef Stefan InstituteJörn Rittweger, MD, PhD, Principal investigator, German Aerospace Center (DLR)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02637921
- Sponsor's protocol ID
- 284438/WP3
- Acronym
- PlanHab
- Status last verified
- Mar 2019
- First submitted
- 1 Dec 2015
- Last updated
- 15 Mar 2019
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Rittweger J, Debevec T, Frings-Meuthen P, Lau P, Mittag U, Ganse B, Ferstl PG, Simpson EJ, Macdonald IA, Eiken O, Mekjavic IB. On the combined effects of normobaric hypoxia and bed rest upon bone and mineral metabolism: Results from the PlanHab study. Bone. 2016 Oct;91:130-8. doi: 10.1016/j.bone.2016.07.013. Epub 2016 Jul 18.
PubMed 27443510
Study at a glance
From the registry record, last updated by the sponsor on 15 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Planetary Habitat Simulation: The Combined Effects of Bed Rest and Normobaric Hypoxia Upon Bone and Mineral Metabolism (WP3)
- ClinicalTrials.gov ID
- NCT02637921
- Acronym / sponsor ID
- PlanHab / 284438/WP3
- Conditions
- Hypoxia, Bone Resorption
- Keywords
- bed rest, bone metabolism
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Collaborators
- Jozef Stefan Institute, DLR German Aerospace Center, KTH Royal Institute of Technology, European Commission
- Study start
- Mar 2012
- Primary completion
- Nov 2013 (actual)
- Study completion
- Sep 2015 (actual)
- First posted
- 22 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bone losses are well known to occur in response to unloading (in microgravity or during immobilisation) and in patients with chronic obstructive airway disease (COPD). However, it is unknown whether there is an interactive effect between hypoxia and musculoskeletal unloading upon bone and mineral metabolism. Fourteen non-obese men, who are otherwise healthy, will undergo 3x 21-day interventions; normobaric normoxic bed rest (NBR; FiO2=21%), normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and normobaric hypoxic bed rest (HBR; FiO2=14%). The effects of hypoxia and bedrest on bone metabolism and phosphor-calcic homeostasis will be assessed (before and during each intervention, and 14 days after each intervention period) using venous blood sampling, 24hr urine collections, and peripheral quantitative computerized tomography (pQCT).
Detailed description
The risk of bone loss in response to immobilization and space flight is widely recognized, with such bone losses occurring predominantly in the legs. Loading forces in the lower extremities are typically low in space and during bed rest, but musculoskeletal loading countermeasures can prevent or reduce bone losses induced in these conditions. Although the primary origin may be of a mechanical nature, bone losses in astronauts and immobilized patients are likely to be modulated by the endocrine and the internal environment.
Bone loss and osteoporosis is also prevalent in those with chronic obstructive pulmonary disease (COPD). The most discussed etiological factors for this condition include lack of physical activity, vitamin-D deficiency, hypogonadism, use of corticosteroids and smoking. However, COPD is associated with tissue hypoxemia and it is unclear whether hypoxia per se will affect bone turnover or metabolism.
The protocol of the current study standardises potential confounding factors, such as physical activity, ambient temperature, hypoxic stimulus and nutritional composition of the diet across all 3 interventions, and aims to extend our knowledge of the effects of hypoxia and bedrest on bone metabolism and phospho-calcic homeostasis.
Fourteen non-obese men, who are otherwise healthy, will be recruited following medical and psychological screening. They will be invited to attend the Olympic Sport Centre, Planica, Slovenia on 3 occasions, with each visit being 31 days in duration and separated by 5 months. Each 31-day visit ('campaign') includes a baseline recording period (5 days), 21 days of intervention, and a recovery period (5 days), with a follow-up visit being carried out 14 days after each intervention. The 3 interventions will be allocated in a randomized, cross over design: i) Normobaric normoxic bed rest (NBR; FiO2=21%), ii) Normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and iii) Normobaric hypoxic bed rest (HBR; FiO2=14%). A standardized, repeating, 14-day dietary menu, comprised of foods commonly consumed in the Slovenian diet, will be applied during all campaigns. Targeted energy intakes will be calculated individually using a modified Benedict-Harris formula, with physical activity factor multipliers of 1.2 for the HBR and NBR campaigns and 1.4 for the HAMB campaign, used to promote energy balance. Body mass will be monitored daily during the campaigns using a gurney incorporating load cells, and whole body composition will be determined before and immediately after each intervention using fan beam dual-emission X-ray absorptiometry. Macronutrient composition of the diet will be approximately 17% protein, 53% carbohydrate and 30% fat, with >1.1g of protein per kg body weight provided per day, and daily salt (sodium chloride) intake being <10g. Food will be provided in weighed portions and subjects will be encouraged to eat all food supplied. However, any food not eaten will be weighed and actual amount consumed recorded in a diet analysis programme.
Participants will have bone mineral content assessed at 5 time points (before, 3 during and one after each intervention) using pQCT scans of the calf and thigh. Horizontal scans will be taken at 4%, 14%, 38%, and 66% of the tibia (assessed from its distal end), and at 4% and 33% of the femur. Twenty-four hour urine collections will be obtained before (2 time points), during (11 time points) and after (3 time points) each intervention, and will be assessed for urinary calcium and phosphate content, and for a marker of bone reabsorption (N-terminal telopeptide). In addition, early morning, fasting venous blood samples will also be taken before (2 time points), and during (5 time points) each intervention. These will be analysed for calcium, phosphate, bone specific alkaline phosphatase, parathyroid hormone, 25-Hydroxyvitamin D, Procollagen-I-N-terminal propeptide and regulators of bone metabolism, (Dickkopf-related protein 1 and Sclerostin).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Hypoxic ambulatory | Active comparator | Other: Hypoxia, Other: Ambulatory, Other: Standardised nutritional intakeParticipants ambulatory in normobaric hypoxia with standardised nutritional intake |
| Hypoxic Bed rest | Experimental | Other: Hypoxia, Other: Bed Rest, Other: Standardised nutritional intakeParticipants are on bed rest in normobaric hypoxia with standardised nutritional intake |
| Normoxic bed rest | Active comparator | Other: Normoxia, Other: Bed Rest, Other: Standardised nutritional intakeParticipants are on bed rest in normobaric normoxia with standardised nutritional intake |
Who may qualify
- Ages
- 25 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Physically and mentally healthy subjects
- Body mass index < 25 kg/m2
- Height 158 - 190 cm
- Waist circumference < 94 cm
- Volunteers that are able to declare their willingness to participate in the entire study
Key exclusion criteria (20 listed)
- Medication required that may interfere with the interpretation of the results
- Bone mineral density (as measured by DEXA) more than 1.5 standard deviations < t score
- Recent sub-standard nutritional status
- Family history of thrombosis or positive response in thrombosis screening procedure.
- (Biochemical analysis of the following parameters: ATIII, High sensitive C-reactive protein, S-Akt., Factor V-Leiden, Prothrombin, Lupus-partial thromboplastin time, Factor II)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hypoxia21 days confinement in normobaric hypoxic (FiO2 = 14%) | Other | Hypoxic Bed rest, Hypoxic ambulatory |
| AmbulatoryParticipants hava a standardized activity level throughout the intervention | Other | Hypoxic ambulatory |
| Normoxia21 days confinement in normobaric normoxic (FiO2 = 21%) environment | Other | Normoxic bed rest |
| Bed RestParticipants remain on supine bed rest throughout the intervention | Other | Hypoxic Bed rest, Normoxic bed rest |
| Standardised nutritional intakeMacronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant | Other | Hypoxic Bed rest, Hypoxic ambulatory, Normoxic bed rest |
Primary outcome
Change in bone mineral content, from baseline
Time frame: 40 days
assessed before (day -5), on days 2, 10 and 21 of the intervention and at the 14-day follow-up visit (40 days after 1st measurement) using pQCT scans of the calf and thigh.
11 secondary outcomes
Change in urinary calcium concentration, from baseline
Time frame: 30 days
Change in urinary phosphate concentration, from baseline
Time frame: 31 days
Change in urinary N-terminal telopeptide concentration, from baseline
Time frame: 31 days
Change in fasting serum calcium concentration, from baseline
Time frame: 26 days
Change in fasting serum phosphate concentration, from baseline
Time frame: 26 days
Change in fasting serum bone specific alkaline phosphatase concentration, from baseline
Time frame: 26 days
Change in fasting serum parathyroid hormone concentration, from baseline
Time frame: 26 days
Change in fasting serum 25-Hydroxyvitamin D concentration, from baseline
Time frame: 26 days
Change in fasting serum Procollagen-I-N-terminal propeptide concentration, from baseline
Time frame: 26 days
Change in fasting serum Dickkopf-related protein 1 concentration, from baseline
Time frame: 26 days
Change in fasting serum Sclerostin concentration, from baseline
Time frame: 26 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Mar 2019.
- Results publication: PubMed 27443510Rittweger J, Debevec T, Frings-Meuthen P, Lau P, Mittag U, Ganse B, Ferstl PG, Simpson EJ, Macdonald IA, Eiken O, Mekjavic IB. On the combined effects of normobaric hypoxia and bed rest upon bone and mineral metabolism: Results from the PlanHab study. Bone. 2016 Oct;91:130-8. doi: 10.1016/j.bone.2016.07.013. Epub 2016 Jul 18.
- Individual participant dataSharing planned: No
Related trials for Hypoxia
Recruiting
Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac Arrest
Out-of-Hospital Cardiac Arrest, Hypoxic-Ischemic Brain Injury
RecruitingObservational study
Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension
Sleep Apnea, Obstructive Sleep Apnea
Recruiting
Ventilator Pressure and Optimization of Compliance and Hemodynamics
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Recruiting
Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers
Chorioamnionitis Affecting Fetus or Newborn, Amnioinfusion
Recruiting
Methodological Study of Exercise and Hypoxic Conditions in Healthy Subjects
Healthy Subjects (HS), Exercise
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Igor Mekjavic, PhD study director
Jozef Stefan Institute
Jörn Rittweger, MD, PhD principal investigator
German Aerospace Center (DLR)
Questions about this trial
What is this clinical trial studying?
A study testing Hypoxia, Ambulatory and Normoxia in people with Hypoxia and Bone Resorption, run by University of Nottingham.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in bone mineral content, from baseline (time frame: 40 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02637921, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2019.